Research programme: alpha-2C adrenoceptor agonists - AstraZenecaAlternative Names: Alpha-2C adrenoceptor agonists research programme - AstraZeneca
Latest Information Update: 20 Oct 2008
At a glance
- Originator AstraZeneca
- Mechanism of Action Alpha 2c adrenoceptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 04 May 2000 New profile
- 04 May 2000 Preclinical development for Pain in USA (Unknown route)